Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | TLR4 | O00206 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399598 | 0.76 | CTSD (0.48) | KMT2AALDH1A1L3MBTL1NPC1RAB9A | |
| Nitroanilide SCHEMBL6001 | 0.73 | L3MBTL1 (0.50) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A | |
| Nitroanilide SCHEMBL5718352 | 0.73 | L3MBTL1 (0.50) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL3956328 | 0.73 | TLR4 (0.56) | CYP11B1CYP11B2KMT2AMEN1TLR4 | |
| SCHEMBL13037068 | 0.73 | HPGD (0.66) | CYP11B1CYP11B2KMT2AMEN1TLR4 | |
| Nitric Acid SCHEMBL4682608 | 0.72 | L3MBTL1 (0.50) | CYP11B1CYP11B2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3956322 | 0.72 | TLR4 (0.48) | CYP11B1CYP11B2KMT2AMEN1TLR4 | |
| SCHEMBL5996779 | 0.72 | CYP11B1 (0.54) | CYP11B1CYP11B2KMT2AMEN1TLR4 | |
| SCHEMBL3956325 | 0.72 | TLR4 (0.48) | CYP11B1CYP11B2KMT2AMEN1TLR4 | |
| Nitroanilide SCHEMBL3094185 | 0.72 | L3MBTL1 (0.48) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107954988-A | A kind of sulfamide derivative, preparation method and its application as NAMPT inhibitor in antitumor drug | 田立志 | 2018-04-24 | — | — | CN | disclosed |
| EP-2417136-B1 | IMIDAZO [1,2-A] PYRIDINE-6-CARBOXAMIDE DERIVATIVES, THEIR USE FOR THE TREATMENT OF COLON CANCER AND THEIR METHOD OF MANUFACTURE | UNIV WITWATERSRAND JOHANNESBURG (ZA) | 2016-01-06 | — | — | EP | disclosed |
| US-8481740-B2 | Imidazo[1,2 a] pyridine-6-carboxamide derivatives, their use for the treatment of colon cancer and their method of manufacture | UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) | 2013-07-09 | — | — | US | disclosed |
| US-20120101122-A1 | IMIDAZO[1,2 A] PYRIDINE 6 CARBOXAMIDE DERIVATIVES, THEIR USE FOR THE TREATMENT OF COLON CANCER AND THEIR METHOD OF MANUFACTURE | UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) | 2012-04-26 | — | — | US | disclosed |
| EP-2417136-A1 | IMIDAZ0Ý1,2-A¨PYRIDINE-6-CARBOXAMIDE DERIVATIVES, THEIR USE FOR THE TREATMENT OF COLON CANCER AND THEIR METHOD OF MANUFACTURE | University Of Witwatersrand, Johannesburg (ZA) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010116302-A1 | IMIDAZ0[1,2-A] PYRIDINE-6-CARBOXAMIDE DERIVATIVES, THEIR USE FOR THE TREATMENT OF COLON CANCER AND THEIR METHOD OF MANUFACTURE | UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101122-A1 | IMIDAZO[1,2 A] PYRIDINE 6 CARBOXAMIDE DERIVATIVES, THEIR USE FOR THE TREATMENT OF COLON CANCER AND THEIR METHOD OF MANUFACTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR1 | CYP11B1 250/4885CYP11B2 385/4885KMT2A 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.